Wedbush Issues Positive Forecast for NovoCure (NASDAQ:NVCR) Stock Price

NovoCure (NASDAQ:NVCR) had its price objective upped by Wedbush from $18.00 to $20.00 in a research note released on Friday morning, Marketbeat reports. The brokerage currently has a neutral rating on the medical equipment provider’s stock.

Several other brokerages have also issued reports on NVCR. Zacks Research lowered shares of NovoCure from a “hold” rating to a “strong sell” rating in a report on Tuesday, July 14th. HC Wainwright upped their price objective on shares of NovoCure from $46.00 to $52.00 and gave the stock a “buy” rating in a report on Thursday. JPMorgan Chase & Co. initiated coverage on NovoCure in a research report on Monday, July 13th. They issued a “neutral” rating and a $17.00 target price on the stock. Evercore restated an “outperform” rating on shares of NovoCure in a research report on Friday, May 1st. Finally, Weiss Ratings upgraded NovoCure from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday, June 1st. Two analysts have rated the stock with a Buy rating, three have issued a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, NovoCure has an average rating of “Hold” and an average target price of $21.20.

NovoCure Trading Down 11.7%

Shares of NovoCure stock opened at $17.65 on Friday. The stock has a 50 day moving average of $16.64 and a 200 day moving average of $14.14. The company has a debt-to-equity ratio of 0.71, a quick ratio of 2.70 and a current ratio of 2.90. The firm has a market capitalization of $2.04 billion, a price-to-earnings ratio of -13.58 and a beta of 0.94. NovoCure has a fifty-two week low of $9.82 and a fifty-two week high of $21.45.

NovoCure (NASDAQ:NVCR) last posted its earnings results on Thursday, July 23rd. The medical equipment provider reported ($0.13) EPS for the quarter, beating analysts’ consensus estimates of ($0.33) by $0.20. NovoCure had a negative return on equity of 44.02% and a negative net margin of 21.25%.The company had revenue of $183.58 million for the quarter, compared to the consensus estimate of $172.44 million. During the same quarter in the previous year, the business earned ($0.36) earnings per share. The company’s revenue for the quarter was up 15.6% on a year-over-year basis. As a group, research analysts predict that NovoCure will post -1.52 earnings per share for the current year.

Insider Activity

In other NovoCure news, CEO Frank X. Leonard sold 34,273 shares of NovoCure stock in a transaction that occurred on Thursday, June 4th. The shares were sold at an average price of $17.93, for a total value of $614,514.89. Following the completion of the sale, the chief executive officer directly owned 459,520 shares of the company’s stock, valued at approximately $8,239,193.60. The trade was a 6.94% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Allyson J. Ocean sold 2,945 shares of the stock in a transaction on Tuesday, June 2nd. The stock was sold at an average price of $15.77, for a total value of $46,442.65. Following the transaction, the director directly owned 11,324 shares in the company, valued at approximately $178,579.48. This represents a 20.64% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 51,943 shares of company stock valued at $893,171 in the last quarter. Insiders own 5.52% of the company’s stock.

Hedge Funds Weigh In On NovoCure

Several institutional investors have recently added to or reduced their stakes in the business. Empowered Funds LLC purchased a new stake in NovoCure in the fourth quarter valued at approximately $33,000. Kestra Advisory Services LLC purchased a new position in NovoCure during the fourth quarter worth approximately $49,000. Larson Financial Group LLC raised its stake in NovoCure by 662.1% during the third quarter. Larson Financial Group LLC now owns 4,100 shares of the medical equipment provider’s stock worth $53,000 after purchasing an additional 3,562 shares during the period. Mirae Asset Global Investments Co. Ltd. boosted its holdings in shares of NovoCure by 25.9% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,442 shares of the medical equipment provider’s stock valued at $70,000 after purchasing an additional 1,120 shares during the last quarter. Finally, Acadian Asset Management LLC purchased a new stake in shares of NovoCure during the 1st quarter valued at $87,000. 84.61% of the stock is currently owned by institutional investors and hedge funds.

Key Stories Impacting NovoCure

Here are the key news stories impacting NovoCure this week:

• Positive Sentiment: NovoCure reported Q2 EPS of -$0.13, beating the consensus loss estimate of -$0.33, while revenue came in at $183.6 million versus expectations of $172.4 million. Revenue also rose 15.6% year over year, signaling improving business momentum.
• Positive Sentiment: The company raised its FY2026 revenue guidance to $710 million-$725 million, above the market’s prior expectation of about $704 million, which suggests management sees continued demand strength.
• Positive Sentiment: HC Wainwright increased its price target on NovoCure to $52 from $46 and maintained a Buy rating, reinforcing optimism around the company’s longer-term earnings potential. Article Title
• Neutral Sentiment: Wedbush also raised its price target to $20 from $18, but kept a Neutral rating, indicating improved expectations without a strong bullish call. Article Title
• Neutral Sentiment: Shares also got a lift from optimism around the company’s brain therapy pipeline and possible FDA-related catalysts, which helped push the stock to new highs as investors priced in further upside. Article Title
• Negative Sentiment: HC Wainwright trimmed its FY2029 EPS estimate slightly to $1.90 from $1.95, a small caution on the company’s very long-term earnings outlook.

About NovoCure

NovoCure is a global oncology company pioneering Tumor Treating Fields (TTFields), a novel anti-mitotic therapy for solid tumors. The company’s non-invasive treatment platforms deliver low-intensity, alternating electric fields designed to disrupt cancer cell division. NovoCure’s approach offers an alternative modality to complement existing therapies in oncology, with a focus on hard-to-treat malignancies.

Founded in 2000 and headquartered in Haifa, Israel, NovoCure maintains a second operational center in Portsmouth, New Hampshire.